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Abstract
Background PF-06439535 is a bevacizumab biosimilar. We aimed to compare the efficacy and safety of PF-06439535 with 
that of reference bevacizumab  (Avastin®) sourced from the EU (bevacizumab-EU), each with paclitaxel and carboplatin, in 
the first-line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC).
Methods In this double-blind, parallel-group study, we recruited patients from 159 centers in 27 countries. Participants were 
randomized 1:1 to receive PF-06439535 plus paclitaxel and carboplatin or bevacizumab-EU plus paclitaxel and carboplatin 
on day 1 of each 21-day cycle for 4–6 cycles, followed by blinded monotherapy with PF-06439535 or bevacizumab-EU until 
disease progression, unacceptable toxicity, withdrawal of consent, or the end of the study. Randomization was stratified by 
region, sex, and smoking history. The primary endpoint was objective response rate (ORR) in accordance with RECIST 1.1, 
based on responses achieved by week 19 and confirmed by week 25.
Results Between 21 May 2015 and 14 November 2016, 719 patients were randomized to the PF-06439535 group (n = 358) 
or the bevacizumab-EU group (n = 361). As of data cutoff for analysis of the primary endpoint (8 May 2017), 45.3% (95% 
confidence interval [CI] 40.01–50.57) of patients in the PF-06439535 group and 44.6% (95% CI 39.40–49.89) of patients in 
the bevacizumab-EU group achieved an objective response by week 19 that was confirmed by week 25. The unstratified ORR 
risk ratio was 1.015 (95% CI 0.863–1.193; 90% CI 0.886–1.163), and the unstratified ORR risk difference was 0.653% (95% 
CI − 6.608 to 7.908); all three CIs fell within pre-specified equivalence margins. Using final data after study completion (22 
December 2017), no notable differences in progression-free survival or overall survival were observed between the groups. 
The most frequently reported grade 3 or higher treatment-emergent adverse events were hypertension, neutropenia, and ane-
mia. There were no clinically meaningful differences in safety, pharmacokinetics, or immunogenicity across treatment groups.
Conclusion Among patients with advanced non-squamous NSCLC, PF-06439535 demonstrated similarity to bevacizumab-
EU in terms of efficacy. Safety profiles for the two treatments were comparable.
Trial Registration ClinicalTrials.gov, NCT02364999.
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1 Introduction
Vascular endothelial growth factor (VEGF) is a key regula-
tor of tumor angiogenesis [1]. Elevated expression of VEGF 
is observed in many cancers and has been associated with 
poorer prognosis, including an increased likelihood of can-
cer recurrence, tumor metastasis, and death [2–4]. Bevaci-
zumab  (Avastin®) is a recombinant humanized monoclonal 
antibody that binds to and inhibits the biological activity of 
VEGF by interrupting its interaction with endothelial cell-
surface receptors [5, 6].
Bevacizumab was licensed by the US Food and Drug 
Administration (FDA) in 2004 for the first-line treatment 
of metastatic colorectal cancer in combination with chemo-
therapy [5]. Authorization in the European Union (EU) 
followed in 2005 [6]. Since that time, bevacizumab has 
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Key Points 
the EU (bevacizumab-EU) and the US (bevacizumab-US), 
and that it exhibits functional similarity to these reference 
products [20]. Nonclinical in vivo studies have provided evi-
dence of similarity between PF-06439535 and bevacizumab-
EU in toxicity, toxicokinetics, and immunogenicity [20]. 
Furthermore, a comparative, single-dose study in healthy 
male volunteers demonstrated the pharmacokinetic (PK) 
similarity of PF-06439535, bevacizumab-EU, and bevaci-
zumab-US, with no marked differences observed in safety 
or immunogenicity [21].
We conducted the current study (B7391003) to compare 
the efficacy and safety of PF-06439535 plus paclitaxel and 
carboplatin with that of bevacizumab-EU plus paclitaxel and 
carboplatin in the first-line treatment of advanced non-squa-
mous NSCLC. Our primary objective was to assess whether 
PF-06439535 demonstrated similarity to bevacizumab-EU, 
based on the confirmed objective response rate (ORR) in 
each treatment group.
2  Methods
2.1  Study Design and Patients
This was a multinational, double-blind, randomized, 
parallel-group study registered at ClinicalTrials.gov 
(NCT02364999) and EudraCT (2014-003878-16). Patients 
were randomized at 159 centers in 27 countries (see Elec-
tronic Supplementary Material [ESM], Table S1). Adult 
patients were eligible for inclusion if they had histologically 
or cytologically confirmed, predominantly non-squamous, 
newly diagnosed Stage IIIB or IV NSCLC (according to 
lung cancer staging criteria of 2010 [22, 23]) or recur-
rent NSCLC. For patients with recurrent disease, at least 
6 months must have elapsed since completing adjuvant or 
neoadjuvant treatment. Additionally, patients had at least one 
measurable lesion per Response Evaluation Criteria in Solid 
Tumors version 1.1 (RECIST 1.1) [24], an Eastern Coopera-
tive Oncology Group (ECOG) performance status of 0 or 
1, and were eligible to receive study treatment of bevaci-
zumab, paclitaxel, and carboplatin based on the local stand-
ard of care for the treatment of advanced or metastatic non-
squamous NSCLC. Key exclusion criteria included known 
central nervous system metastases (treated and stable brain 
metastases were allowed); known sensitizing EGFR muta-
tions or EML4–ALK translocations (patients with unknown 
status were permitted to enroll); prior systemic therapy for 
NSCLC (prior neoadjuvant or adjuvant therapy was allowed 
if surgical resection for primary disease was performed); and 
prior treatment with immunotherapy or bevacizumab. Full 
eligibility criteria can be found in the ESM.
The original protocol (dated 4 November 2014) was 
amended three times; details of the changes can be found in 
This comparative clinical study was designed to dem-
onstrate that there are no clinically meaningful differ-
ences in the efficacy and safety profile of PF-06439535 
(a bevacizumab biosimilar) as compared with reference 
bevacizumab  (Avastin®) sourced from the EU (bevaci-
zumab-EU) in a patient population for which reference 
bevacizumab is indicated.
When PF-06439535 or bevacizumab-EU was combined 
with paclitaxel and carboplatin in the first-line treatment 
of advanced non-squamous non-small-cell lung cancer, 
we identified no notable differences between the two 
treatment groups with respect to efficacy, safety, pharma-
cokinetics, or immunogenicity.
The results confirm the similarity demonstrated in 
earlier analytical, nonclinical, and clinical studies of 
PF-06439535 and reference bevacizumab.
been approved for the treatment of several additional can-
cers, including non-squamous non-small-cell lung cancer 
(NSCLC), recurrent glioblastoma, metastatic renal cell car-
cinoma, cervical cancer, and ovarian cancer [5, 6]. Across 
tumor types, randomized controlled trials have demonstrated 
that bevacizumab plus chemotherapy is associated with ben-
efits such as improved overall survival (OS) and progression-
free survival (PFS) relative to chemotherapy alone [7–9], 
and bevacizumab continues to have a prominent position in 
cancer treatment algorithms [10, 11]. Despite such benefits, 
however, patient access to bevacizumab may be limited, 
owing to factors such as lack of reimbursement and high 
out-of-pocket costs [12].
Biosimilars are biological products that are highly similar 
to a licensed reference biologic, with no clinically meaning-
ful differences in quality characteristics, biological activity, 
safety, or efficacy [13–15]. The introduction of biosimilars 
has been associated with cost savings [16], and the Ameri-
can Society of Clinical Oncology and the European Society 
for Medical Oncology have highlighted the importance of 
biosimilars in enhancing patient access to anticancer thera-
pies and supporting the sustainability of cancer care [17, 18]. 
Biosimilars are developed in a stepwise process of head-to-
head comparison with the reference product in analytical, 
nonclinical, and clinical studies, with biosimilarity deter-
mined based on the totality of evidence [13–15].
PF-06439535 (Zirabev™) is a bevacizumab biosimilar 
[19]. Comprehensive comparative analytical studies have 
established that PF-06439535 has an identical amino acid 
sequence to reference bevacizumab  (Avastin®) sourced from 
PF-06439535 (a Bevacizumab Biosimilar) in Non-Small-Cell Lung Cancer
the final version of the protocol (dated 10 June 2016), which 
is available at ClinicalTrials.gov.
2.2  Randomization and Blinding
Patients were enrolled by study investigators and rand-
omized in a 1:1 ratio to receive either PF-06439535 plus 
paclitaxel and carboplatin or bevacizumab-EU plus pacli-
taxel and carboplatin for 4–6 cycles, followed by blinded 
monotherapy with PF-06439535 or bevacizumab-EU as pre-
viously assigned (ESM, Fig. S1). The randomization sched-
ule was computer-generated by the sponsor and included 
the stratification variables of region (location of the drug 
depot supplying the site), sex (male/female), and smoking 
history (never/ever). The schedule was concealed from the 
sponsor’s personnel directly involved in study conduct and 
was implemented by the study sites using an interactive web 
response system.
Treatment assignments were blinded to patients, inves-
tigators, and the sponsor’s study team. Limited members 
of the sponsor’s study team were unblinded at the time of 
the primary efficacy analysis. Site personnel and patients 
remained blinded until the completion of the study. 
PF-06439535 and bevacizumab-EU were provided by the 
sponsor as blinded supplies in which the external packag-
ing for each vial appeared identical and was identified with 
a unique container number. Paclitaxel and carboplatin were 
branded products or generic equivalents available in the 
local region. Use of nab-paclitaxel in place of paclitaxel 
was not permitted.
2.3  Treatments
On treatment days when PF-06439535 or bevacizumab-
EU was administered in combination with chemotherapy, 
the order of administration was paclitaxel, carboplatin, 
and PF-06439535 or bevacizumab-EU. Treatments were 
administered by intravenous infusion on day  1 of each 
21-day cycle. Paclitaxel was administered at an initial dose 
of 200 mg/m2, carboplatin at an initial dose targeting an 
area under the concentration versus time curve of 6.0 mg/
mL·min, and PF-06439535 or bevacizumab-EU at an initial 
dose of 15 mg/kg. Paclitaxel and carboplatin dose reductions 
were allowed for toxicity. No dose reductions were planned 
for PF-06439535 or bevacizumab-EU, but if deemed neces-
sary the investigator could decrease the dose to 7.5 mg/kg 
after discussion with the sponsor. Patients were pre-med-
icated before paclitaxel administration in order to prevent 
severe hypersensitivity reaction.
After chemotherapy had been discontinued, PF-06439535 
or bevacizumab-EU monotherapy could be administered 
until disease progression (defined per RECIST 1.1), unac-
ceptable toxicity, discretion of the investigator, death, 
withdrawal of consent, or the end of the study, whichever 
came first. The dose and regimen for PF-06439535 and bev-
acizumab-EU were chosen to be consistent with the product 
labeling of bevacizumab-EU. The chemotherapy given and 
the regimens used were considered standard of care.
2.4  Endpoints and Assessments
The primary endpoint was ORR, defined as the percentage 
of patients within each treatment group who achieved a best 
overall response (BOR) of complete response (CR) or partial 
response (PR) by week 19 in accordance with RECIST 1.1, 
which was subsequently confirmed on a follow-up tumor 
assessment by week 25. BOR was derived by the sponsor 
based on tumor measurements reported by the investigator. 
This endpoint was considered sufficiently sensitive to detect 
differences in efficacy between PF-06439535 and bevaci-
zumab-EU. The choice of primary endpoint and the use of 
investigator-reported tumor measurements were agreed with 
regulatory authorities.
Secondary efficacy endpoints were duration of response 
(DOR), 1-year PFS rate, and 1-year OS rate from randomiza-
tion. DOR was calculated only for the subgroup of patients 
with an objective response achieved by week 19 and con-
firmed by week 25. Additional secondary endpoints included 
safety, peak and trough PF-06439535 and bevacizumab-EU 
concentrations at selected cycles up to 1 year from rand-
omization, and incidence of anti-drug antibodies (ADAs; 
including neutralizing antibodies [NAbs]) up to 1 year from 
randomization.
Tumor assessments included computed tomography 
(CT) or magnetic resonance imaging (MRI) scans of the 
head, chest, abdomen (including adrenals), and other dis-
ease sites such as the pelvis if clinically indicated. CT scans 
were performed with contrast media unless contraindicated 
for medical reasons. MRI was only used when considered 
more appropriate than CT or when there was a contraindi-
cation for use of CT with contrast. For a given patient, the 
same method of tumor assessment was used throughout the 
trial. CT or MRI assessments were performed every 6 weeks 
(± 7 days) until week 25 (based on date of randomization). 
After week 25, assessments were performed every 9 weeks 
(± 7 days) until 1 year from randomization. Responses were 
required to be confirmed by a second set of scans obtained 
6 weeks (± 7 days) later in accordance with RECIST 1.1. 
Additionally, brain scans were performed as clinically indi-
cated and at the time of a confirmatory scan for CR/PR. 
Patients who continued to receive study treatment after 
1 year had tumor assessments performed according to local 
standard of care.
Blood samples for assessment of immunogenicity were 
collected pre-dose at specified study cycles and analyzed 
for the presence or absence of ADAs (anti-bevacizumab or 
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anti-PF-06439535 antibodies). A single, sensitive, specific, 
and semi-quantitative electrochemiluminescent immunoas-
say was used. The ADA assay had been validated and used 
biotinylated and ruthenium-labeled PF-06439535 as rea-
gents. Analysis of ADA samples followed a tiered approach 
of screening, confirmation, and titer determination. Only 
those samples confirmed positive for ADAs were further 
tested for NAbs. The NAb analysis was conducted using a 
single, validated, quasi-quantitative enzyme-linked immu-
nosorbent assay (ELISA) that utilized PF-06439535 as a rea-
gent. Analysis of NAb samples followed a tiered approach 
of screening and titer determination.
Drug concentrations of PF-06439535 and bevacizumab-
EU were determined using serum samples collected at pre-
specified time points. Samples were collected pre-dose; in 
addition, post-dose samples were collected 1 h (± 0.5 h) after 
the end of infusion on cycle 1, day 1 and cycle 5, day 1. 
Concentrations were determined using a validated, sensitive, 
and specific ELISA. Immunogenicity and PK analyses were 
carried out at QPS, LLC (Newark, DE, USA).
Safety was characterized by the type, incidence, sever-
ity, timing, seriousness, and relationship to study therapy 
of adverse events (AEs), including cardiotoxicity and 
infusion-related reactions, and laboratory abnormalities. 
Other safety evaluations included physical examinations, 
vital signs, and 12-lead electrocardiogram monitoring. The 
investigator obtained and recorded all observed or volun-
teered AEs, the severity of the events (based on Common 
Terminology Criteria for Adverse Events version 4.03), and 
his or her opinion of the relationship to study treatment. 
Treatment-emergent AEs (TEAEs) were those that occurred 
after the beginning of study treatment, or any pre-existing 
AE that worsened after the beginning of study treatment. 
AEs of special interest were arterial thromboembolic events, 
bleeding/hemorrhage (including pulmonary hemorrhage), 
cardiac disorders, congestive heart failure, hypertension 
(only grade 3 or higher), proteinuria or nephrotic syndrome, 
venous thromboembolic events, gastrointestinal perforations, 
and wound-healing complications.
After discontinuation from treatment, survival status was 
collected by telephone contact every 2 months (± 14 days) 
until death or 1 year from patient randomization. The study 
was considered complete when the last available patient 
completed up to 1 year from randomization plus a 28-day 
follow-up period.
2.5  Statistical Analyses
The primary efficacy analysis for the primary endpoint was 
based on the Miettinen and Nurminen method [25] without 
stratification variables and was carried out in the intent-to-
treat (ITT) population, defined as all patients who were ran-
domized to study treatment. The estimated ORR risk ratio 
and ORR risk difference between the PF-06439535 and bev-
acizumab-EU groups were computed, along with asymptotic 
two-sided 95% and 90% confidence intervals (CIs). Equiva-
lence was determined based on the following criteria agreed 
with regulatory authorities. For the FDA, equivalence was 
considered established if the 90% CI of the ORR risk ratio 
fell within the margin of 0.73–1.37. For Japan’s Pharmaceu-
ticals and Medical Devices Agency (PMDA), equivalence 
was considered established if the 95% CI of the ORR risk 
ratio fell within the margin of 0.729–1.371. Finally, for the 
European Medicines Agency (EMA), equivalence was con-
sidered established if the 95% CI of the ORR risk difference 
fell within the margin of − 13% to 13%.
The equivalence margins above were derived based on 
meta-analysis of three randomized studies of reference beva-
cizumab plus paclitaxel and carboplatin versus paclitaxel 
and carboplatin alone in patients with NSCLC [8, 26, 27]. 
The ORR for reference bevacizumab plus chemotherapy 
was estimated to be approximately 40%, and the ORR for 
chemotherapy alone was estimated to be 21%. The ORR 
risk ratio for bevacizumab plus chemotherapy versus chemo-
therapy alone was 2.17 (95% CI 1.74–2.70). The margin 
of 0.73–1.37 in the current study maintained 43% of the 
effect size estimated from the historical ORR data using 
a log scale, and approximately 50% using a linear scale. 
Assuming an ORR of 38% in both treatment arms, a sam-
ple of 656 patients (328 per treatment arm) would provide 
approximately 85% power for achieving equivalence accord-
ing to the FDA criteria above. Considering a possible ~ 7.5% 
attrition rate for patients reaching evaluation for ORR, a total 
sample of approximately 710 patients (355 per treatment 
arm) was to be randomized. Using the EMA and PMDA 
equivalence criteria, and again assuming an ORR of 38%, 
the planned sample size would provide power of approxi-
mately 86% and 74%, respectively.
As a sensitivity analysis, the Miettinen and Nurminen 
method [25] was also conducted without stratification vari-
ables using the per-protocol (PP) population, defined as all 
patients who were randomized and received PF-06439535 
or bevacizumab-EU as planned and had no major protocol 
deviations. The list of patients not included in the PP popula-
tion and the reasons for exclusion were determined prior to 
unblinding for the primary efficacy analysis. As secondary 
analyses in both the ITT and PP populations, the Miettinen 
and Nurminen method [25] was repeated with additional 
stratification variables (region, sex, and smoking history) 
to assess whether these would affect the ORR risk ratio or 
risk difference.
Time-to-event endpoints were assessed using the 
Kaplan–Meier method. A Cox proportional hazard model 
was used to estimate hazard ratios (HRs); the model included 
treatment and the covariates of region, sex, and smoking 
history. The two treatment groups were compared using a 
PF-06439535 (a Bevacizumab Biosimilar) in Non-Small-Cell Lung Cancer
2-sided log-rank test stratified by region, sex, and smoking 
history.
For the ORR endpoint, if a patient had a missing tumor 
outcome across all visits or had non-evaluable BOR per 
RECIST 1.1, he or she was considered a non-responder and 
was included in the denominator, but not the numerator. For 
the time-to-event endpoints, missing data were censored.
The safety population, defined as all patients who were 
randomized and received at least one dose of study treat-
ment, was used for safety and immunogenicity analyses. 
AEs were summarized by body system and preferred term 
according to the Medical Dictionary for Regulatory Activi-
ties (version 20.1) classification system. The percentage of 
patients with positive ADA and NAb results was summa-
rized for each treatment and each visit. Patients in the PP 
population who had at least one drug concentration meas-
urement post-administration of treatment were included in 
the PK analysis. The drug concentration–time data were 
summarized by descriptive statistics according to treatment.
The primary efficacy analysis for statistical equivalence 
was performed when all patients had completed the week 25 
visit to support the primary endpoint analysis or had discon-
tinued from the disease evaluation period earlier. All other 
analyses presented herein are based on final data after study 
completion. All statistical analyses were conducted as speci-
fied in the statistical analysis plan, which can be accessed at 
ClinicalTrials.gov.
3  Results
3.1  Patient Baseline Characteristics and Disposition
Patients were randomized between 21 May 2015 and 14 
November 2016. The data cutoff date for analysis of the pri-
mary efficacy endpoint was 8 May 2017. The last patient 
visit was on 22 December 2017, with final database release 
on 16 January 2018.
In total, 719 patients were assigned to PF-06439535 
plus paclitaxel and carboplatin (PF-06439535 group; 358 
patients) or bevacizumab-EU plus paclitaxel and carbo-
platin (bevacizumab-EU group; 361 patients) and com-
prised the ITT population (Fig. 1). Of these, 714 patients 
received at least one dose of study drug or chemotherapy and 
were included in the safety population (356 patients in the 
PF-06439535 group and 358 patients in the bevacizumab-
EU group).
Overall, the disposition of patients between treatment 
groups was comparable. Among the 714 patients in the 
safety population, the primary reason for discontinua-
tion of PF-06439535 or bevacizumab-EU was objective 
disease progression or relapse (176 [49.4%] patients in 
the PF-06439535 group and 207 [57.8%] patients in the 
bevacizumab-EU group) (ESM, Table S2). Including the 
survival follow-up period, the most frequent reason for dis-
continuation from the study was death (136 [38.2%] patients 
in the PF-06439535 group and 138 [38.5%] patients in the 
bevacizumab-EU group).
Demographic and baseline characteristics of the ITT pop-
ulation were similar between the treatment groups (Table 1). 
Of the 719 randomized patients, 467 (65.0%) were male. The 
median age was 61.0 years, and more than half of patients 
(58.4%) were 45–64 years of age. The majority of patients 
were White (638 [88.7%] patients) or Asian (76 [10.6%] 
patients). In total, 547 (76.1%) patients had newly diagnosed 
Stage IV disease, while 95 (13.2%) patients presented at 
screening with recurrent disease. Overall, 129 (17.9%) 
patients had received prior resection of primary disease (not 
including biopsies), 35 (4.9%) had received prior systemic 
therapy, and 47 (6.5%) had received prior radiation therapy.
3.2  Treatment Exposure
As of study completion (22 December 2017), the extent of 
exposure was similar between treatment groups in the safety 
population. The mean (standard deviation) duration of treat-
ment was 35.2 (27.19) weeks in the PF-06439535 group 
and 34.9 (25.96) weeks in the bevacizumab-EU group. In 
the PF-06439535 group, the median number of cycles of 
PF-06439535 treatment was 11.0 (range 1–41), with 6.0 
cycles (range 1–6 cycles) of paclitaxel treatment and 6.0 
cycles (range 1–6 cycles) of carboplatin treatment. In the 
bevacizumab-EU group, the median number of cycles of 
bevacizumab-EU treatment was 11.0 (range 1–38), with 6.0 
cycles (range 1–6 cycles) of paclitaxel treatment and 6.0 
cycles (range 1–6 cycles) of carboplatin treatment.
3.3  Primary Efficacy Endpoint
At the time of the data cutoff for the primary efficacy ORR 
analysis (8 May 2017), all randomized patients had com-
pleted the week 25 visit or had discontinued from the disease 
evaluation period earlier. In the ITT population, 45.3% (95% 
CI 40.01–50.57) of patients in the PF-06439535 group and 
44.6% (95% CI 39.40–49.89) of patients in the bevacizumab-
EU group achieved an objective response by week 19 that 
was confirmed by week 25 (Table 2). The unstratified ORR 
risk ratio was 1.015, with a 95% CI of 0.863–1.193 and a 
90% CI of 0.886–1.163. The unstratified ORR risk difference 
was 0.653%, with a 95% CI of − 6.608% to 7.908%. All three 
CIs fell entirely within the equivalence margins described 
earlier (Fig. 2). Thus, similarity between PF-06439535 and 
bevacizumab-EU was demonstrated for ORR, based on the 
pre-specified criteria for each of the three health authorities.
A sensitivity analysis based on the unstratified ORR risk 
ratio and risk difference in the PP population yielded results 
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consistent with those in the ITT population (data cutoff date 
8 May 2017; data not shown). Additional supportive results 
were obtained in ORR analyses adjusted for stratification 
factors, in both the ITT and PP populations (data cutoff date 
8 May 2017; data not shown).
3.4  Secondary Efficacy Endpoints
Analyses of PFS, OS, and DOR were based on final 
data after study completion on 22 December 2017. In 
the ITT population, there were 228 (63.7%) patients in 
the PF-06439535 group and 255 (70.6%) patients in the 
1095 screened
719 randomized 
376 excluded
358 allocated to PF-06439535 group 361 allocated to bevacizumab-EU group
261 discontinued PF-06439535
349 discontinued carboplatin
349 discontinued paclitaxel
262 discontinued bevacizumab-EU
351 discontinued carboplatin
351 discontinued paclitaxel
356 received treatmenta 358 received treatment
2 did not receive treatment
1 had exacerbation of COPD condition
1 met exclusion criteria
3 did not receive treatment
1 withdrew consent
2 mistakenly unblinded 
355 discontinued PF-06439535 
356 discontinued carboplatin 
356 discontinued paclitaxel 
358 discontinued bevacizumab-EU
358 discontinued carboplatin
358 discontinued paclitaxel 
358 included in efficacy analysis (ITT population) 
351 included in efficacy analysis (PP populationc) 
351 included in PK analysis (PK population) 
356 included in safety analysis (safety population) 
361 included in efficacy analysis (ITT population) 
355 included in efficacy analysis (PP populationc)   
354 included in PK analysis (PK population) 
358 included in safety analysis (safety population)
At data cutoff for ORR analysis (8 May 2017): 
179 ongoing in study
137 discontinued from study
109 died
2 protocol violation
9 lost to follow-up
3 objective progression or relapse
0 global deterioration of health status
13 patients refused further follow-up 
1 other
40 alive and had completed survival follow-up
At completion of study (22 December 2017):
163 discontinued from study 
136 died
3 protocol violation
10 lost to follow-up
0 study terminated by sponsor
14 patients refused further follow-up  
0 other 
193 alive and had completed survival follow-up
At data cutoff for ORR analysis (8 May 2017):  
194 ongoing in study
125 discontinued from study
99 died
2 protocol violation
11 lost to follow-up
0 objective progression or relapse
2 global deterioration of health status
10 patients refused further follow-up  
1 other
39 alive and had completed survival follow-up
At completion of study (22 December 2017):
171 discontinued from study 
138 died
2 protocol violation
15 lost to follow-up
1 study terminated by sponsorb 
14 patients refused further follow-up  
1 other
187 alive and had completed survival follow-up
Fig. 1  Participant flow diagram. aOne patient received paclitaxel and 
carboplatin but withdrew before receiving PF-06439535. bPatient was 
indicated as “study terminated by sponsor” by the investigator; how-
ever, this patient was considered to have met the definition of study 
completion (i.e. patient was alive and had completed survival follow-
up as defined by the protocol). cThe most frequently reported reason 
for patients not being included in the PP population was due to being 
randomized but never dosed with PF-06439535 or bevacizumab-EU 
(3 [0.8%] patients in the PF-06439535 group and 3 [0.8%] patients 
in the bevacizumab-EU group). Bevacizumab-EU reference bevaci-
zumab sourced from the European Union, COPD chronic obstructive 
pulmonary disease, ITT intent-to-treat, ORR objective response rate, 
PK pharmacokinetics, PP per-protocol
PF-06439535 (a Bevacizumab Biosimilar) in Non-Small-Cell Lung Cancer
Table 1  Demographic and baseline characteristics (intent-to-treat population)
PF-06439535  
group (N = 358)
Bevacizumab-EU 
group (N = 361)
Sex
 Male 237 (66.2) 230 (63.7)
 Female 121 (33.8) 131 (36.3)
Age
 < 18 years 0 0
 18–44 years 19 (5.3) 17 (4.7)
 45–64 years 198 (55.3) 222 (61.5)
 ≥ 65 years 141 (39.4) 122 (33.8)
 Median (range), years 62.0 (25–87) 61.0 (31–83)
Race
 White 319 (89.1) 319 (88.4)
 Black 3 (0.8) 1 (0.3)
 Asian 36 (10.1) 40 (11.1)
 Other 0 1 (0.3)
Childbearing potential
 Yes 212 (59.2) 197 (54.6)
 No 146 (40.8) 163 (45.2)
 Not reported 0 1 (0.3)
Smoking status
 Never smoked 103 (28.8) 109 (30.2)
 Smoker 127 (35.5) 117 (32.4)
 Ex-smoker 128 (35.8) 135 (37.4)
Histopathological classification
 Mixed adenocarcinoma 3 (0.8) 4 (1.1)
 Adenocarcinoma 348 (97.2) 351 (97.2)
 Large cell carcinoma 6 (1.7) 5 (1.4)
 Other 1 (0.3) 1 (0.3)
Recurrence type
 Newly diagnosed Stage IIIB 48 (13.4) 29 (8.0)
 Newly diagnosed Stage IV 265 (74.0) 282 (78.1)
 Recurrenta 45 (12.6) 50 (13.9)
Time since initial diagnosis of NSCLC
 Median (range), months 1.2 (0.2–210.9) 1.3 (0.1–137.9)
 Missing/not reported 3 (0.8) 3 (0.8)
Screening ECOG performance status
 0 105 (29.3) 122 (33.8)
 1 252 (70.4) 239 (66.2)
 Missing/not reported 1 (0.3) 0
Prior  surgeriesb for primary diagnoses
 No 297 (83.0) 293 (81.2)
 Yes 61 (17.0) 68 (18.8)
Prior systemic therapies for primary diagnoses
 No 343 (95.8) 341 (94.5)
 Yes 15 (4.2) 20 (5.5)
Prior radiation therapies for primary diagnoses
 No 333 (93.0) 338 (93.6)
 Yes 24 (6.7) 23 (6.4)
 Not reported 1 (0.3) 0
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bevacizumab-EU group who had objective progression or 
died without objective progression. The estimated prob-
ability of being progression-free at 1 year was 33.1% (95% 
CI 27.6–38.6) in the PF-06439535 group and 30.9% (95% 
CI 25.7–36.1) in the bevacizumab-EU group (stratified HR 
0.930, 95% CI 0.776–1.114; p = 0.4388) (Fig. 3a). Overall, 
144 (40.2%) patients in the PF-06439535 group and 149 
(41.3%) patients in the bevacizumab-EU group died. The 
estimated probability of being alive at 1 year was 68.0% 
(95% CI 62.7–72.6) in the PF-06439535 group and 66.3% 
(95% CI 61.0–71.1) in the bevacizumab-EU group (strati-
fied HR 0.918, 95% CI 0.729–1.157; p = 0.4726) (Fig. 3b).
Among the 323 patients in the ITT population who 
achieved an objective response by week  19 that was 
confirmed by week 25, the estimated probability of main-
taining response for 1 year was 33.8% (95% CI 25.9–41.9) 
in the PF-06439535 group and 30.8% (95% CI 23.3–38.6) 
in the bevacizumab-EU group (stratified HR 0.790, 95% CI 
0.600–1.039; p = 0.0906). The estimated median DOR was 
8.3 months (95% CI 7.3–10.0) in the PF-06439535 group 
and 6.6 months (95% CI 6.2–8.3) in the bevacizumab-EU 
group.
3.5  Safety
Safety analyses were performed on final data (22 Decem-
ber 2017). In the safety population, 344 (96.6%) patients 
in the PF-06439535 group and 347 (96.9%) patients in the 
Data are presented as number (%) of patients unless otherwise specified
Bevacizumab-EU reference bevacizumab sourced from the European Union, ECOG Eastern Cooperative Oncology Group, N number of patients 
randomized, NSCLC non-small-cell lung cancer
a Patients whose cancer had returned following an initial treatment with surgery, radiation therapy, and/or chemotherapy administered for curative 
intent
b Only included primary tumor resection
Table 1  (continued)
Table 2  Summary of best overall response and ORR based on responses achieved by week  19 and confirmed by week  25 (intent-to-treat 
population)
Data cutoff date 8 May 2017. ORR defined as the percentage of patients within each treatment group who achieved complete response or partial 
response by week 19 of the study in accordance with RECIST version 1.1, which was subsequently confirmed by week 25
Bevacizumab-EU reference bevacizumab sourced from the European Union, CI confidence interval, CR complete response, N number of patients 
randomized, n number of patients with observation, ORR objective response rate, PR partial response, RECIST Response Evaluation Criteria in 
Solid Tumors
a Indeterminate: early death, unevaluable tumor assessment, and early study discontinuations
b Exact method based on F-distribution was used
c Based on 2-sided Miettinen and Nurminen method without stratification variables
PF-06439535  
group (N = 358)
Bevacizumab-EU 
group (N = 361)
Best overall response, n (%)
 Complete response (CR) 9 (2.5) 4 (1.1)
 Partial response (PR) 153 (42.7) 157 (43.5)
 Stable disease 154 (43.0) 166 (46.0)
 Objective progression 15 (4.2) 14 (3.9)
 Indeterminatea 27 (7.5) 20 (5.5)
ORR (CR + PR), n (%) 162 (45.3) 161 (44.6)
 95% exact  CIb, % 40.01–50.57 39.40–49.89
Treatment comparison (vs bevacizumab-EU group)
 Unstratified ORR risk  differencec, % 0.653
 95% CI of  differencec, % − 6.608 to 7.908
Treatment comparison (vs bevacizumab-EU group)
 Unstratified ORR risk  ratioc 1.015
 95% CI of risk  ratioc 0.863–1.193
 90% CI of risk  ratioc 0.886–1.163
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bevacizumab-EU group experienced at least one TEAE 
(Table 3). The most frequently reported all-causality TEAEs 
were alopecia (166 [46.6%] patients in the PF-06439535 
group vs 165 [46.1%] patients in the bevacizumab-EU 
group) and anemia (104 [29.2%] patients vs 108 [30.2%] 
patients).
There were 171 (48.0%) patients in the PF-06439535 
group and 172 (48.0%) patients in the bevacizumab-EU 
group with a TEAE reported at grade 3 or higher. The most 
frequently reported grade 3 or higher TEAEs were hyper-
tension, neutropenia, and anemia (Table 3). Deaths that 
occurred during the treatment period and up to 28 days after 
the last dose of study drug were considered grade 5 TEAEs. 
The incidence of grade 5 TEAEs was similar between the 
two treatment groups (Table 3). Regarding grade 5 TEAEs 
related to PF-06439535 or bevacizumab-EU, there were 
six events in the PF-06439535 group and one event in the 
bevacizumab-EU group. Three of the six deaths (acute myo-
cardial infarction, pneumonia, and pulmonary hemorrhage) 
in the PF-06439535 group were considered to be also related 
to paclitaxel and carboplatin. Grade 5 TEAEs related to 
PF-06439535 or bevacizumab-EU were consistent with the 
complications of underlying disease and the known safety 
profile of reference bevacizumab [5, 6].
Fig. 2  Treatment comparison 
(PF-06439535 group vs beva-
cizumab-EU group) for ORR, 
based on responses achieved 
by week 19 and confirmed by 
week 25 in the intent-to-treat 
population. Panel a depicts 
the unstratified ORR risk ratio 
with 90% and 95% CIs, and 
panel b depicts the unstrati-
fied ORR risk difference with 
95% CI.  Dashed lines indicate 
equivalence margins agreed 
with regulatory authorities in 
the EU, Japan, or the US. Data 
cutoff date 8 May 2017. Analy-
ses based on 2-sided Miet-
tinen and Nurminen method 
without stratification variables. 
Bevacizumab-EU reference 
bevacizumab sourced from the 
European Union, CI confi-
dence interval, ORR objective 
response rate
Risk difference (%) and 95% CI
)UE( 31)UE( 31–
–20 –10 0 10 20
–6.608 7.908
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Risk ratio
5.10.15.0
95% CI 
(Japan)
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0.729 (Japan)
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PF-06439535 group
Bevacizumab-EU group
1-year progression-free 
survival rate (95% CIa)
Median progression-free
survival (95% CIb)
33.1% (27.6–38.6)
30.9% (25.7–36.1) 
9.5 months (7.6–9.7) 
7.7 months (7.6–8.5) 
PF-06439535 group
Bevacizumab-EU group
1-year overall 
survival rate (95% CIa)
Median overall
survival (95% CIb)
68.0% (62.7–72.6) 
66.3% (61.0–71.1) 
19.4 months (16.5–NE) 
17.8 months (15.9–23.5) 
Fig. 3  Kaplan–Meier plots of a progression-free survival and b 
overall survival in the intent-to-treat population. Final data after 
study completion on 22 December 2017. aCI based on product-limit 
method. bCI based on Brookmeyer and Crowley method. cHazard 
ratio based on Cox proportional hazards model stratified by region, 
sex, and smoking history. d2-sided p-value based on log-rank test 
stratified by region, sex, and smoking history. Bevacizumab-EU refer-
ence bevacizumab sourced from the European Union, CI confidence 
interval, NE not estimable
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Serious TEAEs were experienced by 81 (22.8%) patients 
in the PF-06439535 group and 80 (22.3%) patients in the 
bevacizumab-EU group. The most frequently reported seri-
ous TEAEs were pneumonia, febrile neutropenia, and neu-
tropenia, which occurred at a similar incidence between the 
treatment groups (Table 3).
No clinically meaningful differences in the incidence of 
any TEAEs of special interest were identified between the 
groups (ESM, Table S3). The most frequently reported grade 
3 or higher TEAE of special interest was hypertension (34 
[9.6%] patients in the PF-06439535 group and 32 [8.9%] 
patients in the bevacizumab-EU group) (Table 3).
There were no notable differences between the groups 
in laboratory results, maximal post-baseline shifts in blood 
pressure, absolute declines in left ventricular ejection frac-
tion, or electrocardiograms.
Table 3  Summary of TEAEs of all causalities (safety population)
Data are presented as number (%) of patients unless otherwise specified. Final data after study completion on 22 December 2017. Data col-
lected up to 28 days after the last dose of study drug or to start of subsequent anticancer therapy, whichever came first. Except for the number 
of TEAEs, patients were counted only once per treatment in each row. Serious adverse events were determined according to the investigator’s 
assessment. Severity counts were based on the maximum severity or grade of events
Bevacizumab-EU reference bevacizumab sourced from the European Union, N number of patients evaluable for adverse events, TEAE treatment-
emergent adverse event
a Medical Dictionary for Regulatory Activities version 20.1 coding dictionary applied
PF-06439535  
group (N = 356)
Bevacizumab-EU 
group (N = 358)
Number of TEAEs 2442 2470
TEAEs
 Any 344 (96.6) 347 (96.9)
 Serious 81 (22.8) 80 (22.3)
 Grade 3 125 (35.1) 104 (29.1)
 Grade 4 25 (7.0) 44 (12.3)
 Grade 5 21 (5.9) 24 (6.7)
 Led to discontinuation of any treatment 85 (23.9) 86 (24.0)
Grade 3 or higher TEAEs by preferred term in ≥ 5% of patients in either treatment  groupa
 Hypertension 33 (9.3) 31 (8.7)
 Neutropenia 26 (7.3) 32 (8.9)
 Anemia 19 (5.3) 18 (5.0)
Grade 3 or higher TEAEs of special interest by category
 Arterial thromboembolic events 6 (1.7) 6 (1.7)
 Bleeding/hemorrhage (including pulmonary hemorrhage) 8 (2.2) 7 (2.0)
 Cardiac disorders 10 (2.8) 12 (3.4)
 Congestive heart failure 1 (0.3) 3 (0.8)
 Gastrointestinal perforation 0 2 (0.6)
 Hypertension, only grade 3 or higher 34 (9.6) 32 (8.9)
 Proteinuria/nephrotic syndrome 4 (1.1) 5 (1.4)
 Venous thromboembolic events 8 (2.2) 4 (1.1)
Serious TEAEs by preferred term in ≥ 1% of patients in either treatment  groupa
 Pneumonia 8 (2.2) 6 (1.7)
 Febrile neutropenia 5 (1.4) 7 (2.0)
 Neutropenia 4 (1.1) 6 (1.7)
 Disease progression 4 (1.1) 5 (1.4)
 Pulmonary embolism 7 (2.0) 2 (0.6)
 Anemia 2 (0.6) 5 (1.4)
 Asthenia 4 (1.1) 1 (0.3)
 Gastroenteritis 4 (1.1) 0
 Hyponatremia 4 (1.1) 0
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3.6  PK and Immunogenicity
PK and immunogenicity analyses were conducted on final 
data (22 December 2017). In the PK population, mean serum 
concentrations were generally comparable between the two 
treatment groups at all time points measured from baseline 
through cycle 18, day 1 (Fig. 4). No comparison of summary 
statistics of serum concentrations between the two groups 
after this time point was conducted, because such compari-
son was considered to be substantially confounded by the 
limited number of patients at the later time points.
The observed rate of immunogenicity in the safety popu-
lation was low, with comparable percentages of patients with 
ADAs and NAbs observed for the two groups. In the overall 
post-treatment assessment, five (1.5%) of 339 patients in 
the PF-06439535 group and five (1.4%) of 350 patients in 
the bevacizumab-EU group were reported ADA-positive 
(Table 4). This included one patient in the bevacizumab-
EU group who was also ADA-positive at baseline. All 
nine patients with treatment-emergent ADAs (five in the 
PF-06439535 group and four in the bevacizumab-EU group) 
had low titers, and the treatment-emergent ADAs appeared 
to be transient. In the overall post-treatment assessment, of 
the five patients who reported positive ADA status in the 
PF-06439535 group, none was NAb-positive; of the five 
patients who reported positive ADA status in the bevaci-
zumab-EU group, three (0.9%) were NAb-positive (data for 
baseline NAb incidence not shown). Given the low number 
of patients with ADAs, the association between immuno-
genicity and safety could not be evaluated. No apparent 
impact of the low-titer ADAs on PK was observed.
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Fig. 4  Mean serum concentrations of PF-06439535 and bevaci-
zumab-EU in the PK population. Final data after study completion 
on 22 December 2017. Triangle or square and bar represent the mean 
with standard deviation. Concentrations are pre-dose (0-h time point) 
unless otherwise noted. Summary statistics calculated by setting con-
centration values below the LLOQ (< 250  ng/mL) to 0. Unplanned 
readings excluded. Samples with a time deviation of > 20% or any 
positive time deviation from the 0-h planned time point excluded. 
End of treatment and early withdrawal samples excluded. Standard 
deviation not shown for the 0-h time point at cycle 1, day 1 because 
the bars would be shorter than the height of the triangle and square 
symbols. There were 20 patients in the PF-06439535 group and 17 
patients in the bevacizumab-EU group with measurable pre-dose con-
centrations above the LLOQ on cycle 1, day 1. Patients with measur-
able pre-dose concentrations > 5% of apparent Cmax (serum concen-
tration at 2.5-h time point) on cycle 1, day 1 were excluded from the 
summary analysis. After this pre-specified exclusion, six patients in 
the PF-06439535 group and seven patients in the bevacizumab-EU 
group with measurable pre-dose concentrations on cycle 1, day 1 
were included in the summary. Bevacizumab-EU reference bevaci-
zumab sourced from the European Union, C cycle, Cmax maximum 
concentration, h hour(s), LLOQ lower limit of quantification, PK 
pharmacokinetics
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4  Discussion
Based on pre-specified equivalence margins agreed with the 
FDA, EMA, and PMDA, this study demonstrated similar-
ity between PF-06439535 and bevacizumab-EU in terms of 
ORR, when each treatment was combined with paclitaxel 
and carboplatin in the first-line treatment of advanced non-
squamous NSCLC. There were no clinically meaningful 
differences observed between groups for secondary efficacy 
endpoints, safety, PK, or immunogenicity, as expected. 
Furthermore, no new safety signals were identified in the 
PF-06439535 group compared with the established safety 
profile of reference bevacizumab. The observation that 
serum concentrations of PF-06439535 and bevacizumab-
EU were generally similar between the two groups at mul-
tiple time points supports the findings from the previous 
single-dose study that established PK similarity between 
PF-06439535, bevacizumab-EU, and bevacizumab-US in 
healthy male volunteers [21].
Our study was designed in accordance with guidance on 
demonstrating biosimilarity from the FDA and the EMA [14, 
28], in conjunction with scientific advice from regulatory 
authorities. Although survival-based endpoints are impor-
tant when seeking to establish clinical benefit for a novel 
anticancer agent, such endpoints are less suitable for dem-
onstrating biosimilarity [29]. Whereas PFS and OS may be 
influenced by factors such as tumor burden and subsequent 
lines of therapy, ORR is a direct measure of drug antitu-
mor activity and hence is considered a sensitive endpoint 
for detecting potential product-related differences between 
a biosimilar and reference product [29, 30]. Indeed, ORR 
has been used as the primary endpoint in comparative clini-
cal studies of other oncology biosimilars [31–34]. Addi-
tionally, bevacizumab plus paclitaxel and carboplatin has 
a well-characterized safety and efficacy profile as first-line 
therapy for patients with advanced non-squamous NSCLC 
[8]. Considering these factors, the design of the current 
study was considered sufficiently sensitive for detecting any 
clinically meaningful differences between PF-06439535 and 
bevacizumab-EU, should they exist.
This study incorporated design features from historical 
trials of reference bevacizumab plus paclitaxel and carbopl-
atin [8, 26, 27], and patient eligibility criteria were similar to 
those in a pivotal phase III study of reference bevacizumab 
in NSCLC (ECOG 4599) [8]. Although cross-trial compari-
sons should be made with caution, ORR in the ECOG 4599 
arm treated with reference bevacizumab plus paclitaxel and 
carboplatin was 35%, and was therefore similar to the response 
rates observed in the current study (45.3% in the PF-06439535 
group and 44.6% in the bevacizumab-EU group). Notably, 
median OS in the ECOG 4599 study arm treated with refer-
ence bevacizumab plus paclitaxel and carboplatin was shorter 
than that observed in both arms in our study, at 12.3 months 
as compared with 19.4 months (PF-06439535 group) and 
17.8 months (bevacizumab-EU group) [8]. Certain advances 
since the conduct of the historical trial may have contrib-
uted to these differences; for example, patients in the current 
study were able to receive follow-up anticancer therapy with 
treatments that were not available at the time of the ECOG 
4599 study, including pemetrexed and immune-checkpoint 
inhibitors such as nivolumab [35, 36].
One potential limitation of our study was that patient 
recruitment was weighted towards a minority of the 27 
enrolling countries. Ten countries (Russia, Ukraine, Roma-
nia, Hungary, Poland, Germany, Turkey, India, Japan, and 
Greece) accounted for 85.4% of the total enrollment, with 
45.6% of the overall study population recruited from cent-
ers in Russia and Ukraine only. Additionally, subsequent 
Table 4  Summary of ADA incidence (safety population)
Data are presented as number (%) of patients unless otherwise specified. Final data after study completion on 22 December 2017. Percentages 
based on the number of patients evaluated at each visit. All samples taken prior to dosing. ADA-positive sample defined as ADA titer ≥ 2.29, 
ADA-negative sample defined as ADA titer < 2.29
ADA anti-drug antibody, bevacizumab-EU reference bevacizumab sourced from the European Union, N number of patients who received study 
drug
a For calculation of the overall incidence of post-treatment ADA, the denominator was the number of patients with at least one post-cycle 1 ADA 
sample tested. Patients with a positive ADA sample at any time post-cycle 1 were defined as having an overall positive ADA status
Visit Criteria PF-06439535  
group (N = 356)
Bevacizumab-EU 
group (N = 358)
Cycle 1 (prior to treatment) Number of patients evaluated 352 353
Positive 1 (0.3) 3 (0.8)
Negative 350 (99.4) 350 (99.2)
Not tested 1 (0.3) 0
Overall (post-treatment)a Number of patients evaluated 339 350
Positive 5 (1.5) 5 (1.4)
Negative 334 (98.5) 345 (98.6)
 N. Reinmuth et al.
lines of treatment might have been affected by drug avail-
ability discrepancies across different countries. However, as 
the proportions of patients enrolled from each country were 
well balanced between the treatment groups, the compari-
son of PF-06439535 and bevacizumab-EU was not adversely 
affected. Of note, high rates of recruitment from Russia and 
countries in Eastern Europe have been observed in other 
recent comparative clinical studies of oncology biosimilars 
[32, 37, 38].
With respect to the applicability of the results to current 
practice, it is noteworthy that bevacizumab added to a plati-
num-based chemotherapy doublet remains a first-line option 
in the treatment of advanced or metastatic non-squamous 
NSCLC negative for molecular testing [10, 11]. However, 
the recent introduction of immune-checkpoint inhibitors has 
led to an expanded range of available first-line therapeutic 
options [11]. In this new era, we anticipate that bevacizumab 
may have an important role when used in combination with 
immunotherapy. Results from the IMpower150 trial, for 
example, showed that the addition of atezolizumab to beva-
cizumab plus carboplatin and paclitaxel in the first-line treat-
ment of non-squamous metastatic NSCLC led to a signifi-
cant improvement in both PFS and OS, with the PFS benefit 
observed in key clinical and biomarker subgroups [39].
Addressing escalating healthcare costs and improving 
patient access to treatment remain priorities in the treatment 
of cancer, and biosimilars are expected to have a key role 
[17, 18]. In addition to PF-06439535, several potential beva-
cizumab biosimilars are in clinical development, and in most 
instances confirmatory clinical studies have been conducted 
in patients with advanced non-squamous NSCLC [31, 40]. 
Furthermore, the bevacizumab biosimilar ABP 215 has been 
licensed in the US and authorized in the EU [41, 42].
5  Conclusions
In conclusion, this study in patients with advanced non-
squamous NSCLC demonstrated similarity between 
PF-06439535 and bevacizumab-EU in terms of the primary 
efficacy endpoint of ORR, when each was administered in 
combination with paclitaxel and carboplatin as first-line 
treatment. No notable differences were observed between 
the groups in PFS or OS. There were no clinically meaning-
ful differences in safety profile, and similar PK and immu-
nogenicity results were observed across treatment groups. 
These results confirm the similarity demonstrated in earlier 
analytical, nonclinical, and clinical studies of PF-06439535 
and reference bevacizumab [20, 21].
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